Compounds > emd 53998
Page last updated: 2024-09-05

emd 53998 and Muscle Disorders

emd 53998 has been researched along with Muscle Disorders in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ochala, J1
Fowler, VM; Gokhin, DS; Lunardi, J; Monnier, N; Ochala, J; Pénisson-Besnier, I; Quijano-Roy, S; Romero, NB1

Reviews

1 review(s) available for emd 53998 and Muscle Disorders

ArticleYear
Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?
    Neuromuscular disorders : NMD, 2010, Volume: 20, Issue:2

    Topics: Calcium; Calcium Signaling; Cardiotonic Agents; Contractile Proteins; Humans; Hydrazones; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Pyridazines; Quinolines; Simendan; Thiadiazines

2010

Other Studies

1 other study(ies) available for emd 53998 and Muscle Disorders

ArticleYear
Congenital myopathy-causing tropomyosin mutations induce thin filament dysfunction via distinct physiological mechanisms.
    Human molecular genetics, 2012, Oct-15, Volume: 21, Issue:20

    Topics: Actin Cytoskeleton; Adult; Aged; Child; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Mutation; Quinolines; Thiadiazines; Tropomyosin

2012